Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
OBJECTIVE: To determine if the dipeptidyl peptidase-4 inhibitor vildagliptin more effectively inhibits glucagon levels than the sulfonylurea glimepiride during a meal. RESEARCH DESIGN AND METHODS: Glucagon responses to a standard meal were measured at baseline and study end point (mean 1.8 years) i...
Main Authors: | Ahrén, B, Foley, J, Ferrannini, E, Matthews, DR, Zinman, B, Dejager, S, Fonseca, V |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2010
|
Similar Items
-
Changes in prandial glucagon levels after 2 years treatment with vildagliptin or glimepiride
by: Ahren, B, et al.
Published: (2009) -
Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
by: Ferrannini, E, et al.
Published: (2009) -
Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study.
by: Matthews, DR, et al.
Published: (2010) -
Comparison of safety and efficacy of glimepiride-metformin and vildagliptin- metformin treatment in newly diagnosed type 2 diabetic patients
by: Surendra Kumar
Published: (2021-01-01) -
Effect of Metformin Monotherapy and Combination Therapy with Glimepiride on Lipid Profile in Drug Naive Type-2 Diabetes Patients: A Prospective Observational Study
by: Anchit Pareek, et al.
Published: (2023-04-01)